Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update
Entered into an exclusive global license agreement with Organon to commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%) that includes a $10...
Day: March 31, 2022
Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform and is designed to transform the standard of care for...
Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update
NORCROSS, Ga., March 31, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting
REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic...
VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer
Three leading experts in gynecological oncology will discuss treatment landscape and unmet needs in ovarian cancer Event on Monday, April...
Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and...
Konica Minolta Healthcare Appoints New President and CEO
Fumi Hayashida, KMHA Fumi Hayashida, President and CEO, Konica Minolta Healthcare Americas, Inc.WAYNE, N.J., March 31, 2022 (GLOBE NEWSWIRE) --...
Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association
Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality of Life for Alzheimer’s Patients...
Portage Biotech Provides Update on Clinical-Stage and Development Programs
Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued development Company continues to work...
OrthoPediatrics to Participate in the 21st Annual Needham Virtual Healthcare Conference
WARSAW, Ind., March 31, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on...
Rapid Therapeutic Science Laboratories Announces 1-for-25 Reverse Stock Split
DALLAS, Texas, March 31, 2022 (GLOBE NEWSWIRE) -- Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) ("Rapid Therapeutic" or the "Company"),...
Science 37® Adds Acclaimed Researcher and Oncologist, Dr. Shaalan Beg to Bolster Therapeutic Depth
Addition of Dr. Beg provides Science 37 with expertise to apply more decentralized clinical trial methodologies to the industry’s largest...
Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
Funds to support clinical development of INX-315, the company’s lead Cyclin-Dependent Kinase 2 inhibitor Sid Subramony, Ph.D., of Boxer Capital...
Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:...
Acerus Announces Amendments to Loan Facility
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it...
Agile Therapeutics® Announces First Twirla® Commercial Targeting Gen Z
Partners with Award-Winning Director Maya Albanese “Patch and Play” introduces the features of the Twirla (levonorgestrel and ethinyl estradiol) transdermal...
Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study
CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that...
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
EB-101 pivotal phase 3 VIITAL™ study in RDEB achieves target enrollment; top-line data expected in third quarter of 2022; gained...
CloudMD Announces Cost Optimization and Operational Integration Activities
Identification and elimination of $7.5 million of annualized run-rate costs, focusing on future growth and sustainable profitabilityCost optimization activities will...
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show...
